 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU has announced early positive in vitro results of its SARS-CoV-2 COVID-19 anti-viral, recombinant human interferon alpha-2b rhIFN2b or AP-003. The company said AP-003s first proposed target indication is for people at higher risk to develop severe COVID-19 disease and the data are from the Dr Stephen Barr Laboratory and state-of-the-art ImPaKT Facility at Western University UWO. 